The success rate of online illicit drug transactions during a global pandemic.

Background And Aims: In the months following the onset of the COVID-19 pandemic, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA; 2020) observed an increased use of cryptomarkets, which led them to question whether cryptomarkets constituted a more convenient channel via which to distribute illicit drugs without any in-person contact. However, as more countries' borders closed, the likelihood is that cryptomarkets have been negatively impacted. We aim to measure and understand the success rate of transactions on cryptomarkets during the ongoing COVID-19 pandemic, through recourse to self-reported data that documents the outcome of cryptomarket transactions.

Preliminary findings of the impact of COVID-19 on drugs crypto markets.

Background: The COVID-19 pandemic has had unprecedented consequences on the world economy. The impact of the pandemic on illicit drug market remains scant. We expose the potential consequences the COVID-19 pandemic could have on the ability of people who use drugs to source their illicit drugs via cryptomarkets.

Nonmedical prescription psychiatric drug use and the darknet: A cryptomarket analysis.

Background: Nonmedical prescription psychiatric drug use (NMPDU) is an increasing global health problem, with recent concern focusing on darknet cryptomarkets as sources of procurement. There is a shortage of evidence regarding comparative worldwide NMPDU trends, due in part to data collection difficulties. This problem is particularly marked for non-opioid drugs, particularly those psychiatric drugs which act on the central nervous system (CNS) and have high misuse potential and are associated with high levels of dependency and fatal overdose.

Effect of restricting the legal supply of prescription opioids on buying through online illicit marketplaces: interrupted time series analysis.

Objective: To examine the effect on the trade in opioids through online illicit markets ("cryptomarkets") of the US Drug Enforcement Administration's ruling in 2014 to reschedule hydrocodone combination products.

Design: Interrupted time series analysis.

Setting: 31 of the world's largest cryptomarkets operating from October 2013 to July 2016.

Assessing market competition and vendors' size and scope on AlphaBay.

Background: Since 2011, drug market participants have traded illegal drugs through cryptomarkets, a user-friendly infrastructure in which drug market participants can conduct business transactions. This study assesses market competition and the size and scope of drug vendors' activities on one of the largest cryptomarkets, AlphaBay, in order to better understand the challenges that drug vendors face when selling on this venue.

Methods: Relying on data collected from AlphaBay, we calculate the degree of competition within the drug market using the Herfindhal-Hirshmann Index (HHI).

An island apart? Risks and prices in the Australian cryptomarket drug trade.

Background: Australia has a reputation as an anomaly with regard to cryptomarket drug trading, with seemingly disproportionately high levels of activity given its relatively small size, high prices and anecdotal accounts of it being a destination where many foreign-based vendors will not sell. This paper aims to investigate these claims from a risk and prices perspective.

Methods: By analysing data for over 60,000 drug products available for purchase from eight cryptomarkets in January 2016 this work builds a descriptive picture of the Australian online market in comparison to the rest of the world, before moving onto analyse the prices of drugs available to Australian consumers, both online and though conventional drug supply routes.

Going international? Risk taking by cryptomarket drug vendors.

Background: Since 2011, we have witnessed the rise of 'dark net' drug marketplaces known as cryptomarkets. Cryptomarkets operate on the same model as eBay as they provide a platform where authorized vendors can set up a virtual shop and place listings. Building on a growing body of literature that seeks to understand cryptomarket participants, this paper seeks to explain the decision of cryptomarket vendors to take on risk.

Hidden wholesale: The drug diffusing capacity of online drug cryptomarkets.

Background: In spite of globalizing processes 'offline' retail drug markets remain localized and - in recent decades - typically 'closed', in which dealers sell primarily to known customers. We characterize drug cryptomarkets as 'anonymous open' marketplaces that allow the diffusion of drugs across locales. Where cryptomarket customers make stock-sourcing purchases for offline distribution, the cryptomarket may indirectly serve drug users who are not themselves cryptomarket customers, thereby increasing the drug diffusing capacity of these marketplaces.